Zimmer submits Monogram robot to FDA
Zimmer Biomet submitted its autonomous Monogram robot for FDA clearance, aiming for approval in 2027. The company acquired Monogram in 2025 for $177M. Clinical trials showed no safety events, with potential time savings and accuracy improvements. CEO Ivan Tornos expects FDA review may involve back-and-forth due to the technology's novelty.
How this was made

The 30-second read
Why it matters
The filing introduces a new regulatory milestone that could affect Zimmer Biomet's growth outlook and valuation.
Market read
First‑time FDA 510(k) submission for an autonomous surgical robot, a material regulatory event for a mid‑cap medical‑device firm.
What to watch
Potential cost overruns in scaling the autonomous platform and surgeon adoption rates.
Background
Zimmer Biomet acquired Monogram Technologies in 2025 and is now seeking clearance for a fully autonomous version of the robot, differentiating it from its existing Rosa system.
Ticker impact
Zimmer Biomet filed a 510(k) submission for its autonomous Monogram orthopedic robot, a new regulatory filing not previously reported.
likely modest upside as investors anticipate FDA approval timeline.
Regulatory filings for novel medical devices often boost stock ahead of clearance, especially for a mid‑cap device maker.
Market effects
May signal increased competition in autonomous orthopedic robotics, affecting peers like Stryker (SYK).
U.S. medical‑device sector could see modest uplift.
Limited to U.S. device market; no immediate global ripple.
Counterpoint
If FDA delays or requires additional data, the stock could face downside pressure.
Key entities
- CompanyZimmer Biomet
Medical device maker pursuing autonomous orthopedic robot.
- CompanyMonogram Technologies
Developer of the Monogram robot acquired by Zimmer Biomet.




